About Forge Biologics
Forge Biologics is a company based in Columbus (United States) founded in 2020 by Jaysson Eicholtz and Timothy Miller was acquired by Ajinomoto in November 2023.. Forge Biologics has raised $250 million across 4 funding rounds from investors including Ajinomoto, Marshall Wace and Citadel. Forge Biologics offers products and services including AAV Manufacturing Solutions, Plasmid DNA, and FUEL Platform. Forge Biologics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Columbus, United States
- Founders Jaysson Eicholtz, Timothy Miller
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Forge Biologics
Forge Biologics offers a comprehensive portfolio of products and services, including AAV Manufacturing Solutions, Plasmid DNA, and FUEL Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides end-to-end manufacturing for AAV therapies in development stages.
Offers plasmid DNA for gene therapy applications and research.
Supports gene therapy programs with integrated manufacturing tools.
Unlock access to complete
Unlock access to complete
Funding Insights of Forge Biologics
Forge Biologics has successfully raised a total of $250M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $90 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series C — $90.0M
-
First Round
First Round
(21 Jul 2020)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2022 | Amount | Series C - Forge Biologics | Valuation | Drive Capital , Aisling Capital |
|
| Jan, 2022 | Amount | Debt – Conventional - Forge Biologics | Valuation |
investors |
|
| Apr, 2021 | Amount | Series B - Forge Biologics | Valuation | RA Capital Management |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Forge Biologics
Forge Biologics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Ajinomoto, Marshall Wace and Citadel. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on pre-seed and seed stage investments
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location | |
|
Private debt funds are managed across multiple sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Forge Biologics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Forge Biologics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Forge Biologics Comparisons
Competitors of Forge Biologics
Forge Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Forge Biologics
Frequently Asked Questions about Forge Biologics
When was Forge Biologics founded?
Forge Biologics was founded in 2020.
Where is Forge Biologics located?
Forge Biologics is headquartered in Columbus, United States. It is registered at Columbus, Ohio, United States.
Who is the current CEO of Forge Biologics?
Timothy Miller is the current CEO of Forge Biologics. They have also founded this company.
Is Forge Biologics a funded company?
Forge Biologics is a funded company, having raised a total of $250M across 4 funding rounds to date. The company's 1st funding round was a Series B of $120M, raised on Jul 21, 2020.
What does Forge Biologics do?
Forge Biologics was founded in 2020 and is headquartered in Columbus, United States. Gene therapeutic solutions are developed by the company within the biotechnology sector, targeting rare and monogenic diseases as well as certain cancers. Specific products include FBX-101, which addresses infantile Krabbe disease; FBX-201, aimed at rare monogenic conditions; and FBX-301, focused on rare diseases and oncology applications. Operations emphasize the advancement of these therapies for clinical use.
Who are the top competitors of Forge Biologics?
Forge Biologics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Forge Biologics offer?
Forge Biologics offers AAV Manufacturing Solutions, Plasmid DNA, and FUEL Platform.
Who are Forge Biologics's investors?
Forge Biologics has 10 investors. Key investors include Ajinomoto, Marshall Wace, Citadel, RA Capital, and MidCap Financial.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.